Flumazenil reverses the drowsiness and sedation that occurs when patients take a class of psychoactive drugs called benzodiazepines. The estimated U.S. market size for the drug is about $4 million.
Claris currently has 16 drug approvals, with 23 pending. The company expects more market approvals before the end of the year.
More articles on supply chain:
FDA fast tracks experimental drug to treat Parkinson’s
Roche’s Zika test earns FDA emergency use authorization
Mylan to introduce generic EpiPen at half the price
